These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15657349)

  • 21. Gossypol induces apoptosis in human PC-3 prostate cancer cells by modulating caspase-dependent and caspase-independent cell death pathways.
    Zhang M; Liu H; Tian Z; Griffith BN; Ji M; Li QQ
    Life Sci; 2007 Jan; 80(8):767-74. PubMed ID: 17156797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
    Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
    Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo monitoring response to chemotherapy of human diffuse large B-cell lymphoma xenografts in SCID mice by 1H and 31P MRS.
    Huang MQ; Nelson DS; Pickup S; Qiao H; Delikatny EJ; Poptani H; Glickson JD
    Acad Radiol; 2007 Dec; 14(12):1531-9. PubMed ID: 18035282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells.
    Oliver CL; Bauer JA; Wolter KG; Ubell ML; Narayan A; O'Connell KM; Fisher SG; Wang S; Wu X; Ji M; Carey TE; Bradford CR
    Clin Cancer Res; 2004 Nov; 10(22):7757-63. PubMed ID: 15570010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B-cell lymphoma (DLBCL).
    Markovic O; Marisavljevic D; Cemerikic V; Perunicic M; Savic S; Filipovic B; Mihaljevic B
    Eur J Haematol; 2011 Mar; 86(3):246-55. PubMed ID: 21198858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo.
    Ackler S; Mitten MJ; Chen J; Clarin J; Foster K; Jin S; Phillips DC; Schlessinger S; Wang B; Leverson JD; Boghaert ER
    Br J Pharmacol; 2012 Oct; 167(4):881-91. PubMed ID: 22624727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
    Xia Y; Li ZM; Shi YX; Xia ZJ; Jiang WQ; Huang HQ
    Ai Zheng; 2009 Feb; 28(2):146-9. PubMed ID: 19550126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular mechanisms of (-)-gossypol-induced apoptosis in human prostate cancer cells.
    Huang YW; Wang LS; Chang HL; Ye W; Dowd MK; Wan PJ; Lin YC
    Anticancer Res; 2006; 26(3A):1925-33. PubMed ID: 16827126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma.
    Mohammad RM; Diwakaran H; Maki A; Emara MA; Pettit GR; Redman B; al-Katib A
    Leuk Res; 1995 Sep; 19(9):667-73. PubMed ID: 7564478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
    Godfrey JK; Nabhan C; Karrison T; Kline JP; Cohen KS; Bishop MR; Stadler WM; Karmali R; Venugopal P; Rapoport AP; Smith SM
    Cancer; 2019 Jun; 125(11):1830-1836. PubMed ID: 30707764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The combined modality therapy of diffuse histology non-Hodgkin's lymphoma with cyclophosphamide, adriamycin, vincristine, prednisone (CHOP) and total body irradiation.
    Weick JK; Antunez A; Kraus TA; Fabian CJ; Dixon D
    Int J Radiat Oncol Biol Phys; 1983 Aug; 9(8):1205-7. PubMed ID: 6347997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma.
    Vitolo U; Botto B; Capello D; Vivenza D; Zagonel V; Gloghini A; Novero D; Parvis G; Calvi R; Ariatti C; Milan I; Bertini M; Boccomini C; Freilone R; Pregno P; Orsucci L; Palestro G; Saglio G; Carbone A; Gallo E; Gaidano G
    Leukemia; 2002 Feb; 16(2):268-75. PubMed ID: 11840294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non Hodgkin's lymphoma: a Pediatric Oncology Group study.
    Laver JH; Mahmoud H; Pick TE; Hutchinson RE; Weinstein HJ; Schwenn M; Weitzman S; Murphy SB; Ochoa S; Shuster JJ;
    Leuk Lymphoma; 2001 Jul; 42(3):399-405. PubMed ID: 11699405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic antitumoral activity and induction of apoptosis by novel pan Bcl-2 proteins inhibitor apogossypolone with adriamycin in human hepatocellular carcinoma.
    Mi JX; Wang GF; Wang HB; Sun XQ; Ni XY; Zhang XW; Tang JM; Yang DJ
    Acta Pharmacol Sin; 2008 Dec; 29(12):1467-77. PubMed ID: 19026166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinicopathological features of primary cardiac CD5-positive and bcl-2 and C-MYC double expression diffuse large B-cell lymphoma].
    Zhang F; Luo DL; Chen Y; Liu J; Luo LQ; He J; Yan JH; Xu J; Luo XL; Liu YH
    Zhonghua Bing Li Xue Za Zhi; 2019 Dec; 48(12):951-954. PubMed ID: 31818069
    [No Abstract]   [Full Text] [Related]  

  • 39. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma.
    Coiffier B
    Semin Oncol; 2002 Apr; 29(2 Suppl 6):18-22. PubMed ID: 12040530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone.
    Chen YB; Hochberg EP; Feng Y; Neuberg D; Rawal B; Motyckova G; Fisher DC; McAfee SL; Spitzer TR; Lacasce AS
    Leuk Lymphoma; 2010 May; 51(5):789-96. PubMed ID: 20367136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.